 |
6 Diseases |  |
2 Trials |
|
2 Trials |  |
63 News |  |
| 12» |
- | Mirvaso (brimonidine tartrate) / Galderma
Journal: Symptomatic bradycardia associated with topical brimonidine gel (Mirvaso) administration: a case report. (Pubmed Central) - Jul 24, 2024
This is owing to the increased risk of systemic absorption, which as in this case report, may present with bradycardia. This case reiterates the importance of completing a full medication history including all topical and parenteral medications in patients with arrhythmia.
- | Epsolay (microencapsulated benzoyl peroxide cream 5%) - Sol / Gel, Mirvaso (brimonidine tartrate) / Galderma
Journal: Comparison table: Some topical drugs for rosacea. (Pubmed Central) - Jan 31, 2024
This case reiterates the importance of completing a full medication history including all topical and parenteral medications in patients with arrhythmia. No abstract available
- | Epsolay (microencapsulated benzoyl peroxide cream 5%) - Sol / Gel, Mirvaso (brimonidine tartrate) / Galderma
Journal: Drugs for rosacea. (Pubmed Central) - Jan 31, 2024
No abstract available No abstract available
- | Mirvaso (brimonidine tartrate) / Galderma
Phase classification: Aqueous Humor Dynamics and Brimonidine (clinicaltrials.gov) - Nov 28, 2023
P1, N=35, Completed, Sponsor: University of Nebraska
No abstract available Phase classification: P=N/A --> P1
- | Journal: Minocycline foam (Zilxi) for rosacea. (Pubmed Central) - Jan 29, 2021
Phase classification: P=N/A --> P1 No abstract available
- | Mirvaso (brimonidine tartrate) / Galderma
Trial completion: The Effect of Brimonidine (clinicaltrials.gov) - Oct 9, 2019
P4, N=13, Completed, Sponsor: Wake Forest University Health Sciences
No abstract available Active, not recruiting --> Completed
- | brimonidine tartrate (CD07805/47) / Galderma Laboratories
Clinical, Journal: Case Report: Allergic Contact Dermatitis to Topical Brimonidine Demonstrated With Patch Testing: Insights on Evaluation of Brimonidine Sensitization. (Pubmed Central) - Sep 8, 2019
Active, not recruiting --> Completed No abstract available
- | Mirvaso (brimonidine tartrate) / Galderma
Enrollment closed, Enrollment change: The Effect of Brimonidine (clinicaltrials.gov) - Aug 4, 2019
P4, N=13, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
No abstract available Not yet recruiting --> Active, not recruiting | N=20 --> 13
- | Mirvaso (brimonidine tartrate) / Galderma
New P4 trial: The Effect of Brimonidine (clinicaltrials.gov) - May 21, 2019
P4, N=20, Not yet recruiting, Sponsor: Wake Forest University Health Sciences
- | Mirvaso (brimonidine tartrate) / Galderma
Enrollment change, Trial termination: Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations (clinicaltrials.gov) - Apr 16, 2019
P3, N=6, Terminated, Sponsor: The Hospital for Sick Children
Not yet recruiting --> Active, not recruiting | N=20 --> 13 N=20 --> 6 | Recruiting --> Terminated; Poor enrollment, lack of feasibility
- | Mirvaso (brimonidine tartrate) / Galderma
Trial completion: Treatment of Asian Flushing Syndrome With Topical Alpha Agonists (clinicaltrials.gov) - Apr 1, 2019
P1, N=20, Completed, Sponsor: University of California, San Francisco
N=20 --> 6 | Recruiting --> Terminated; Poor enrollment, lack of feasibility Recruiting --> Completed
- | Mirvaso (brimonidine tartrate) / Galderma
New P1 trial: Pilocarpine and Brimonidine in Patients With Monofocal Lenses (clinicaltrials.gov) - Jan 31, 2019
P1, N=33, Recruiting, Sponsor: Massachusetts Eye and Ear Infirmary
- | Mirvaso (brimonidine tartrate) / Galderma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: BRIMOCAN: The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients (clinicaltrials.gov) - Jan 9, 2019
P2, N=2, Terminated, Sponsor: Heinrich-Heine University, Duesseldorf
Recruiting --> Completed N=24 --> 2 | Trial completion date: Apr 2019 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Dec 2018; It is no longer practicable to complete the trial
- | Mirvaso (brimonidine tartrate) / Galderma
Trial completion date, Trial primary completion date: Treatment of Asian Flushing Syndrome With Topical Alpha Agonists (clinicaltrials.gov) - Oct 25, 2018
P1, N=20, Recruiting, Sponsor: University of California, San Francisco
N=24 --> 2 | Trial completion date: Apr 2019 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Dec 2018; It is no longer practicable to complete the trial Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Feb 2019
- | Mirvaso (brimonidine tartrate) / Galderma
Enrollment open: Treatment of Asian Flushing Syndrome With Topical Alpha Agonists (clinicaltrials.gov) - Jul 17, 2018
P1, N=20, Recruiting, Sponsor: University of California, San Francisco
Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Feb 2019 Not yet recruiting --> Recruiting
- | Mirvaso (brimonidine tartrate) / Galderma
Phase classification, HEOR, Adherence: Internet Surveys and Their Impact on Adherence for Rosacea (clinicaltrials.gov) - Jun 13, 2018
P4, N=20, Completed, Sponsor: Wake Forest University Health Sciences
Not yet recruiting --> Recruiting Phase classification: P2 --> P4
- | Mirvaso (brimonidine tartrate) / Galderma
Phase classification, HEOR, Adherence: Internet Surveys and Their Impact on Adherence for Rosacea (clinicaltrials.gov) - Jun 11, 2018
P2, N=20, Completed, Sponsor: Wake Forest University Health Sciences
Phase classification: P2 --> P4 Phase classification: P=N/A --> P2
- | Mirvaso (brimonidine tartrate) / Galderma
Enrollment open, Trial completion date, Trial primary completion date: Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations (clinicaltrials.gov) - Apr 19, 2018
P3, N=20, Recruiting, Sponsor: The Hospital for Sick Children
Phase classification: P=N/A --> P2 Not yet recruiting --> Recruiting | Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Dec 2018
- | Mirvaso (brimonidine tartrate) / Galderma
New P1 trial: Treatment of Asian Flushing Syndrome With Topical Alpha Agonists (clinicaltrials.gov) - Apr 12, 2018
P1, N=20, Not yet recruiting, Sponsor: University of California, San Francisco
- | Mirvaso (brimonidine tartrate) / Galderma
Trial completion: Aqueous Humor Dynamics and Brimonidine (clinicaltrials.gov) - Mar 9, 2018
P=N/A, N=35, Completed, Sponsor: University of Nebraska
Not yet recruiting --> Recruiting | Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Dec 2018 Not yet recruiting --> Completed
- | Mirvaso (brimonidine tartrate) / Galderma
Trial completion: Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias (clinicaltrials.gov) - Jan 5, 2018
P4, N=19, Completed, Sponsor: Merete Haedersdal
Not yet recruiting --> Completed Recruiting --> Completed
- | Mirvaso (brimonidine tartrate) / Galderma
Trial completion, Trial primary completion date, HEOR, Adherence: Internet Surveys and Their Impact on Adherence for Rosacea (clinicaltrials.gov) - Oct 16, 2017
P=N/A, N=20, Completed, Sponsor: Wake Forest University Health Sciences
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Jun 2017
- | Mirvaso (brimonidine tartrate) / Galderma
Enrollment open: BRIMOCAN: The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients (clinicaltrials.gov) - Jul 24, 2017
P2, N=24, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- | Mirvaso (brimonidine tartrate) / Galderma
New P2 trial: BRIMOCAN: The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients (clinicaltrials.gov) - May 31, 2017
P2, N=24, Not yet recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
- |||| Mirvaso (brimonidine tartrate) / Galderma
Trial completion, Trial primary completion date: BR14004: A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso (clinicaltrials.gov) - Apr 6, 2017
P4, N=101, Completed, Sponsor: Galderma Brasil Ltda.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Feb 2017
- Mirvaso (brimonidine tartrate) / Galderma
New trial, HEOR, Adherence: Internet Surveys and Their Impact on Adherence for Rosacea (clinicaltrials.gov) - Feb 9, 2017
P=N/A, N=20, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
- |||| Mirvaso (brimonidine tartrate) / Galderma
Trial completion, Trial primary completion date: MOSAIC: MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. (clinicaltrials.gov) - Jan 17, 2017
P4, N=188, Completed, Sponsor: Galderma
Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Feb 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2016
- ||||| Mirvaso (brimonidine tartrate) / Galderma
New P4 trial: BR14004: A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso (clinicaltrials.gov) - Aug 5, 2016
P4, N=100, Recruiting, Sponsor: Galderma Brasil Ltda.
- ||| Mirvaso (brimonidine tartrate) / Galderma
Enrollment closed, Trial primary completion date: MOSAIC: MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. (clinicaltrials.gov) - Jun 20, 2016
P4, N=188, Active, not recruiting, Sponsor: Galderma
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2016
- ||| Mirvaso (brimonidine tartrate) / Galderma
Trial completion: Mirvaso (clinicaltrials.gov) - May 18, 2016
P=N/A, N=302, Completed, Sponsor: Galderma
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2016 Recruiting --> Completed
- ||| Mirvaso (brimonidine tartrate) / Galderma
New P3 trial: Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations (clinicaltrials.gov) - May 6, 2016
P3, N=20, Not yet recruiting, Sponsor: The Hospital for Sick Children
- Mirvaso (brimonidine tartrate) / Galderma
Enrollment open, Adherence: Internet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea (clinicaltrials.gov) - May 6, 2016
P4, N=20, Recruiting, Sponsor: Wake Forest School of Medicine
Recruiting --> Completed Not yet recruiting --> Recruiting
- Mirvaso (brimonidine tartrate) / Galderma
New P4 trial: Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias (clinicaltrials.gov) - May 4, 2016
P4, N=20, Recruiting, Sponsor: Merete Haedersdal
- Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment change, Trial withdrawal: BRITE: Brimonidine Tartrate for the Treatment of Injection Related Erythema (clinicaltrials.gov) - Apr 25, 2016
P4, N=0, Withdrawn, Sponsor: Biogen
Not yet recruiting --> Recruiting N=32 --> 0 | Not yet recruiting --> Withdrawn
- |||| Mirvaso (brimonidine tartrate) / Galderma
Enrollment open: MOSAIC: MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. (clinicaltrials.gov) - Feb 11, 2016
P4, N=188, Recruiting, Sponsor: Galderma
N=32 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- |||| Mirvaso (brimonidine tartrate) / Galderma
Trial completion: Mirvaso in Use Study (clinicaltrials.gov) - Jan 21, 2016
P4, N=205, Completed, Sponsor: Galderma Laboratories, L.P.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Mirvaso (brimonidine tartrate) / Galderma
New P4 trial, Adherence: Internet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea (clinicaltrials.gov) - Jan 20, 2016
P4, N=20, Not yet recruiting, Sponsor: Wake Forest School of Medicine
- ||| Mirvaso (brimonidine tartrate) / Galderma
New trial: Mirvaso (clinicaltrials.gov) - Dec 22, 2015
P=N/A, N=330, Recruiting, Sponsor: Galderma
- ||||| Mirvaso (brimonidine tartrate) / Galderma
New P4 trial: MOSAIC: MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. (clinicaltrials.gov) - Nov 27, 2015
P4, N=188, Not yet recruiting, Sponsor: Galderma
- | Plegridy (PEG-interferon ?-1a) / Biogen
New P4 trial: BRITE: Brimonidine Tartrate for the Treatment of Injection Related Erythema (clinicaltrials.gov) - Oct 5, 2015
P4, N=32, Not yet recruiting, Sponsor: Biogen
- ||||||| Mirvaso (brimonidine tartrate) / Galderma
Trial completion, Enrollment closed: Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea (clinicaltrials.gov) - Mar 19, 2015
P3, N=462, Completed, Sponsor: Actavis Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Mirvaso (brimonidine tartrate) / Galderma
New P2 trial: Effect of CD07805/47 Gel in Rosacea Flushing (clinicaltrials.gov) - Nov 24, 2014
P2, N=34, Completed, Sponsor: Galderma R&D
- |||||||||| Mirvaso (brimonidine tartrate) / Galderma
New P3 trial: Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea (clinicaltrials.gov) - Nov 13, 2014
P3, N=462, Active, not recruiting, Sponsor: Actavis Inc.
- Mirvaso (brimonidine tartrate) / Galderma
Enrollment change, Trial withdrawal: Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema (clinicaltrials.gov) - Nov 6, 2014
P3, N=0, Withdrawn, Sponsor: Galderma R&D
Active, not recruiting --> Completed N=260 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Mirvaso (brimonidine tartrate) / Galderma
New P4 trial: Mirvaso in Use Study (clinicaltrials.gov) - Sep 28, 2014
P4, N=250, Recruiting, Sponsor: Galderma Laboratories, L.P.
- ||||| Mirvaso (brimonidine tartrate) / Galderma
Enrollment change, Trial initiation date, Trial primary completion date: Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema (clinicaltrials.gov) - Sep 19, 2014
P3, N=260, Not yet recruiting, Sponsor: Galderma R&D
N=260 --> 0 | Not yet recruiting --> Withdrawn N=84 --> 260 | Initiation date: Aug 2014 --> Feb 2015 | Trial primary completion date: Feb 2015 --> Sep 2015
- |||| Mirvaso (brimonidine tartrate) / Galderma
Trial primary completion date: Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema (clinicaltrials.gov) - Jun 4, 2014
P3, N=84, Not yet recruiting, Sponsor: Galderma R&D
N=84 --> 260 | Initiation date: Aug 2014 --> Feb 2015 | Trial primary completion date: Feb 2015 --> Sep 2015 Trial primary completion date: Sep 2014 --> Feb 2015
- ||||| Mirvaso (brimonidine tartrate) / Galderma
Trial initiation date: Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema (clinicaltrials.gov) - Jun 4, 2014
P3, N=84, Not yet recruiting, Sponsor: Galderma R&D
Trial primary completion date: Sep 2014 --> Feb 2015 Initiation date: Mar 2014 --> Aug 2014
- | Mirvaso (brimonidine tartrate) / Galderma
Trial completion, Patient reported outcomes: Patient-Reported Outcome Of Facial Erythema (PROOF) (clinicaltrials.gov) - Jan 15, 2014
P3, N=92, Completed, Sponsor: Galderma
Initiation date: Mar 2014 --> Aug 2014 Recruiting --> Completed
- ||||||| Mirvaso (brimonidine tartrate) / Galderma
Trial completion: Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea (clinicaltrials.gov) - Nov 11, 2013
P3, N=114, Completed, Sponsor: Galderma R&D
Recruiting --> Completed Active, not recruiting --> Completed